SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Cardiome -- CRME
CRME 2.330-2.1%May 16 4:00 PM EDT
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: kenhott who wrote (240)3/17/2008 3:31:21 PM
From: idos  Read Replies (1) of 285
 
The interim results include data from patients that have not completed 90 days of follow up (and they are considered "event free"). It is expected that a certain % of these patients will relapse by day 90. Therefore, the final data might not be as good as in the interim analysis.
This is probably the reason that the 300mg dose was not stat-sig different from the placebo in the phase IIb (it was better than the placebo in the phase IIa which had a shorter follow up time).
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News